Subject: Chart on PZOO is Rocking So is the News

SCV Client Spotlight
Chart on PZOO is Rocking So is the News
Hot Stock to WatchHot Stock to Watch

Company: Medical Marijuana Inc. (Pink Sheets: MJNA)

End of Day:

Price: 0.15

Change (%): - 0.009 (5.66)

Volume: 7,293,047
MJNA Chart

Medical Marijuana, Inc.'s HempMeds Premier Sponsor of National Marijuana Business Conference

HempMeds Showcases Retail-Ready Cannabidiol (CBD) Hemp Oil Products Available in All 50 U.S. States and Territories

SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) - Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to inform shareholders and the general public that HempMeds™ - a corporate portfolio company, exclusive master distributor and contracted marketing company - is the premier sponsor of the 3rd annual Marijuana Business Conference. The conference will be held November 12-14 at the Rio All-Suites Hotel & Casino in Las Vegas, Nevada, and feature more than 125 vendors and host an estimated 2,000 attendees. (Note: Visit the conference website for admission guidelines and pricing.)

“From the NFL addressing concussions and consumers ranging from toddlers to seniors, the nation is waking up to taking action and lifting the prohibition on cannabis,” states Andrew Hard, spokesperson for HempMeds™. “This week the nation voted on medical cannabis use and the topic is top of mind with the public. It is perfect timing for HempMeds™ to be the premier sponsor of the 3rd annual National Marijuana Business Conference in Las Vegas.”

Continue Reading

Top PerformerYesterday's Top Performer

Pazoo Inc. (OTCQB: PZOO)

End of Day:

Price: 0.0397

Change (%): + 0.0032 (8.77)

Volume: 1,483,272
PZOO Chart

Pazoo Medical Marijuana Partner MA and Associates, LLC Secures First Client Signing Exclusive Master Testing Services Agreement

WHIPPANY, NJ / ACCESSWIRE / November 7, 2014 / Pazoo, Inc. (OTCQB: PZOO) (P2Z.BE) (German WKN#: A1J3DK), is pleased to report that MA & Associates, LLC has signed its first agreement with a customer for the testing of their product. Product is expected to be available for testing in February 2015. MA & Associates LLC’s clients will be cultivation facilities. These cultivation facilities need to have product tested and labeled prior to delivery to dispensaries.

Pazoo’s and MA & Associates, LLC’s management teams have both maintained that utilizing Steep Hill Labs technology, coupled with the strong management team in place gives MA & Associates, LLC a clear cut competitive advantage in the marijuana testing market. To take this competitive advantage a step further, MA & Associates, LLC will seek to capture market share by being first to market. The build out of its testing laboratory began in October, ensuring that MA & Associates will be operationally ready well in advance of first product being ready for testing. Architectural drawings and renderings of the facility were completed several weeks ago. The testing lab will be located on Western Avenue. A rendering of the facility can be seen below this release.

Continue Reading

Other Small Cap News

Company: Nuvilex, Inc. (OTCQB: NVLX)

Nuvilex Applies in Australia for the Orphan Drug Designation for Pancreatic Cancer Treatment

SILVER SPRING, Md., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted, through its subsidiary Nuvilex Australia, an application to the Therapeutic Goods Administration (TGA) in Australia to obtain the Orphan Drug Designation for its pancreatic cancer treatment. This submission follows similar applications to the United States Food and Drug Administration and the European Medicines Agency in the European Union (EU). Like those in the U.S. (7 years) and the EU (10 years), granting of the Orphan Drug Designation carries with it a significant period of marketing exclusivity. In Australia this period is 5 years.

Nuvilex's CEO and President, Kenneth L. Waggoner, commented, "The application for the Orphan Drug Designation in Australia is the third such application made to the drug regulatory authorities in major areas of the world. In order for the Orphan Drug Designation to be granted to a particular drug or treatment, the target disease must be considered life-threatening and 'rare.' Pancreatic cancer, no matter where it occurs in the world, is undoubtedly life-threatening and, in our opinion, its prevalence in Australia classifies it as a rare disease. It is expected that this application to the TGA will be reviewed relatively quickly, and we may have a decision on it before the end of the year."

Continue Reading

Company: Nhale Inc. (OTCQB: NHLE)

Oregon Legislation Clears Way for Nhale (NHLE) to Move Towards Definitive Agreement

HOUSTON, TX--(Marketwired - Nov 7, 2014) - As proponents celebrate the passage of the initiative which allows adults in Oregon to possess and grow marijuana for personal use, Nhale Inc. (OTCQB: NHLE) is proceeding with due diligence related to negotiations with a prospective Oregon grower.

This week, voters in Oregon and Alaska followed Colorado and Washington State in passing legislation to legalize cannabis for recreational use. The historic votes reflect victories for pro-legalization advocates hoping to bring legal marijuana to additional states in 2016. Pot entrepreneurs in Oregon are now making plans to open retail shops. The state already has a medical marijuana system in place.

Continue Reading

Market News

By Christopher S. Rugaber: AP

US employers add 214K jobs; rate dips to 5.8 pct.

WASHINGTON (AP) - Three days after voters registered their sourness about the U.S. economy, the government said Friday that employers added a solid 214,000 jobs in October, extending the healthiest pace of hiring in eight years.

The Labor Department also said a combined 31,000 more jobs were added in August and September than it had previously estimated. Employers have now added at least 200,000 jobs for nine straight months - the longest such stretch since 1995.

The burst of hiring lowered the unemployment rate to 5.8 percent from 5.9 percent. It is the lowest rate since July 2008. Yet workers' average hourly pay rose only slightly, a glaring weak spot in an otherwise solid report.

Continue Reading

By Abigail Stevenson:

Cramer Remix: Stocks for the next 25 years

Jim Cramer has always been a proponent of long-term investing. With CNBC's 25th Anniversary celebration on Thursday, Cramer is not just thinking about investments for the next quarter. He's thinking about the next 25 years.

Specifically, what stocks given to an infant today could be used to pay down their college debt and make them money in the future?

To do that kind of investing, Cramer thinks that investors have to think big. He has three generational themes that he thinks will have to stand the test of future time.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks